Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.45 |
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | DUT | P33316 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13015478 | 0.77 | MAOB (0.58) | MAOBLMNAPGRBRD4PDE3B | |
| SCHEMBL30627401 | 0.77 | MAOB (0.58) | MAOBLMNAPGRBRD4PDE3B | |
| SCHEMBL9741319 | 0.76 | MAOB (0.42) | MAOBCA12CA1CA9PGR | |
| SCHEMBL22605464 | 0.74 | OPRM1 (0.45) | PGR | |
| SCHEMBL30957389 | 0.73 | CA12 (0.55) | LMNACA12CA1CA9MAPT | |
| SCHEMBL2305162 | 0.73 | CA12 (0.55) | LMNACA12CA1CA9MAPT | |
| SCHEMBL28967652 | 0.72 | MAOB (0.62) | MAOBLMNAPGRBRD4 | |
| SCHEMBL21759900 | 0.72 | ADORA3 (0.39) | MAOBLMNACA12CA1CA9 | |
| SCHEMBL30128499 | 0.72 | ADORA3 (0.39) | MAOBLMNACA12CA1CA9 | |
| SCHEMBL12056344 | 0.71 | LMNA (0.53) | MAOBLMNAPGRBRD4PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025108411-A1 | EP300/CBP REGULATOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京沐华生物科技有限责任公司 | 2025-05-30 | — | — | WO | disclosed |
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-11-25 | — | — | US | disclosed |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI), INC. (CN) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257380-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | MAOB 1809/4885LMNA 1083/4885CA12 3371/4885 |
| US-20210363146-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, NTRK1, ERBB2 | MAOB 1503/4885LMNA 713/4885CA12 2471/4885 |
| US-20210315999-A1 | TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE | MUSK, ERBB2, NTRK1 | MAOB 1809/4885LMNA 1083/4885CA12 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.